AngioDynamics Company Leadership

ANGO Stock  USD 6.99  0.16  2.34%   
AngioDynamics' insiders are aggressively buying. The analysis of insiders' sentiment of trading AngioDynamics stock suggests that virtually all insiders are extremely bullish at this time. AngioDynamics employs about 748 people. The company is managed by 13 executives with a total tenure of roughly 50 years, averaging almost 3.0 years of service per executive, having 57.54 employees per reported executive.
James Clemmer  CEO
President CEO, Director
Chad Campbell  President
Senior Vice President and General Manager, Vascular Access

AngioDynamics' Insider Buying Vs Selling

100

 
Selling
 
Buying

Latest Trades

2024-10-10Warren Nighan JrAcquired 100 @ 6.08View
2024-10-08Stephen A TrowbridgeAcquired 1700 @ 5.86View
2024-10-07Warren Nighan JrAcquired 768 @ 6.09View
2024-04-08James C ClemmerAcquired 10000 @ 6.7View
Monitoring AngioDynamics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.

AngioDynamics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with AngioDynamics' future performance. Based on our forecasts, it is anticipated that AngioDynamics will maintain a workforce of about 750 employees by December 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

AngioDynamics Management Team Effectiveness

The company has return on total asset (ROA) of (0.0612) % which means that it has lost $0.0612 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7785) %, meaning that it created substantial loss on money invested by shareholders. AngioDynamics' management efficiency ratios could be used to measure how well AngioDynamics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to grow to -0.73. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, AngioDynamics' Debt To Assets are very stable compared to the past year.
As of the 26th of November 2024, Common Stock Shares Outstanding is likely to drop to about 30 M. In addition to that, Net Loss is likely to grow to about (44.8 M)

AngioDynamics Workforce Comparison

AngioDynamics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 69,029. AngioDynamics claims roughly 748 in number of employees contributing just under 2% to equities under Health Care industry.

AngioDynamics Profit Margins

The company has Profit Margin (PM) of (0.83) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.13.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.590.509
Fairly Up
Very volatile

AngioDynamics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AngioDynamics insiders, such as employees or executives, is commonly permitted as long as it does not rely on AngioDynamics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, AngioDynamics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-09-01
1.7
34
20
 1,056,757 
 63,960 
2023-09-01
0.881
37
42
 1,361,559 
 450,619 
2022-09-01
1.8667
28
15
 220,408 
 121,779 
2022-06-01
0.2
1
5
 6,022 
 23,057 
2022-03-01
1.0
2
2
 11,000 
 1,777 
2021-12-01
0.3333
2
6
 22,748 
 49,943 
2021-09-01
0.9796
48
49
 726,626 
 388,157 
2021-06-01
0.4
2
5
 19,351 
 36,552 
2021-03-01
1.0
2
2
 73,000 
 7,027 
2020-09-01
1.0
22
22
 661,809 
 101,791 
2020-03-01
1.0
2
2
 23,580 
 980.00 
2019-12-01
7.0
7
1
 108,408 
 736.00 
2019-09-01
0.75
30
40
 549,233 
 448,351 
2019-06-01
0.2857
2
7
 13,300 
 27,096 
2018-09-01
1.7857
25
14
 292,745 
 24,178 
2018-06-01
0.4
4
10
 41,650 
 67,931 
2017-12-01
0.6
3
5
 41,409 
 79,691 
2017-09-01
1.8421
35
19
 453,386 
 166,882 
2017-06-01
0.0455
1
22
 14,000 
 4,862,567 
2017-03-01
0.5
1
2
 14,000 
 28,000 
2016-12-01
0.3333
2
6
 50,000 
 5,000,000 
2016-09-01
1.2727
28
22
 389,948 
 4,624,865 
2016-06-01
0.75
3
4
 500,000 
 17,806 
2015-09-01
1.1143
39
35
 429,609 
 125,124 
2015-06-01
2.0
2
1
 19,649 
 4,649 
2015-03-01
0.3333
1
3
 18,100 
 36,619 
2014-09-01
1.8
36
20
 416,843 
 43,453 
2014-06-01
1.0
2
2
 16,500 
 16,448 
2013-12-01
2.8571
20
7
 212,407 
 52,693 
2013-09-01
2.0625
33
16
 331,424 
 24,965 
2013-03-01
3.0
9
3
 216,808 
 5,946 
2012-12-01
0.3846
5
13
 68,000 
 36,718 
2012-09-01
3.0
33
11
 268,247 
 14,955 
2012-06-01
3.6667
11
3
 104,209 
 4,589 
2012-03-01
0.5455
6
11
 103,000 
 42,916 
2011-12-01
4.0
4
1
 322,500 
 200,000 
2011-09-01
3.7143
26
7
 629,617 
 12,483 
2011-06-01
1.0
1
1
 2,091 
 2,091 
2011-03-01
2.5
5
2
 103,000 
 10,119 
2010-12-01
2.5
5
2
 151,000 
 50,000 
2010-09-01
1.8333
22
12
 295,250 
 75,702 
2010-06-01
3.0
3
1
 52,591 
 2,091 
2010-03-01
0.5
2
4
 4,500 
 306,298 
2009-12-01
0.8
4
5
 55,628 
 25,152 
2009-09-01
11.5
23
2
 226,709 
 50,800 
2009-06-01
3.0
3
1
 9,091 
 2,091 
2009-03-01
2.0
10
5
 399,693 
 22,267 
2008-12-01
1.0
1
1
 21,000 
 0.00 
2008-09-01
18.0
18
1
 151,313 
 20,000 
2008-06-01
3.0
3
1
 6,106 
 2,091 
2008-03-01
2.0
2
1
 5,000 
 2,000 
2007-09-01
13.5
27
2
 239,775 
 10,200 
2007-06-01
1.0
4
4
 53,500 
 12,368 
2007-03-01
0.1176
2
17
 5,955 
 71,743 
2006-12-01
0.5333
8
15
 185,546 
 173,159 
2006-09-01
0.7619
16
21
 61,993 
 58,182 
2006-06-01
0.5714
8
14
 12,624 
 23,686 
2006-03-01
0.5
11
22
 30,500 
 59,000 
2005-12-01
0.3421
13
38
 20,062 
 63,124 
2005-09-01
0.5517
16
29
 78,900 
 62,112 
2005-06-01
0.6296
17
27
 51,838 
 53,103 
2005-03-01
0.5
11
22
 28,546 
 57,092 
2004-12-01
1.3333
8
6
 1,735,843 
 9,242,006 
2004-06-01
1.1667
7
6
 78,400 
 99,319 

AngioDynamics Notable Stakeholders

An AngioDynamics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AngioDynamics often face trade-offs trying to please all of them. AngioDynamics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AngioDynamics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
James ClemmerPresident CEO, DirectorProfile
Chad CampbellSenior Vice President and General Manager, Vascular AccessProfile
David HelselSenior Vice President - Global OperationsProfile
Warren NighanSenior Vice President-Senior Vice President Quality & Regulatory AffairsProfile
Kim SeaburySenior Vice President Information TechnologyProfile
Benjamin DavisSenior Vice President Business DevelopmentProfile
Stephen TrowbridgeSr. VP, General Counsel and Assistant SecretaryProfile
Laura PiccininiSenior InternationalProfile
Scott CenteaSenior TherapiesProfile
Richard RosenzweigGen VPProfile
Marna BronfenMooreSenior ResourcesProfile
Juan SernaSenior AffairsProfile
Saleem CheeksVice CommunicationsProfile

About AngioDynamics Management Performance

The success or failure of an entity such as AngioDynamics often depends on how effective the management is. AngioDynamics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AngioDynamics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AngioDynamics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.77)(0.73)
Return On Capital Employed(0.43)(0.41)
Return On Assets(0.58)(0.55)
Return On Equity(0.90)(0.85)

AngioDynamics Workforce Analysis

Traditionally, organizations such as AngioDynamics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AngioDynamics within its industry.

AngioDynamics Manpower Efficiency

Return on AngioDynamics Manpower

Revenue Per Employee406.3K
Revenue Per Executive23.4M
Net Loss Per Employee246.5K
Net Loss Per Executive14.2M
Working Capital Per Employee136.5K
Working Capital Per Executive7.9M
When determining whether AngioDynamics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AngioDynamics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Angiodynamics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Angiodynamics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.05)
Revenue Per Share
7.249
Quarterly Revenue Growth
(0.14)
Return On Assets
(0.06)
Return On Equity
(0.78)
The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.